US FDA to address challenges to medtech innovation at 15 March public workshop
This article was originally published in SRA
The public meeting at which the US Food and Drug Administration plans to solicit feedback on certain actions proposed in its initiative on accelerating the development and regulatory evaluation of innovative medical devices is set to take place tomorrow1,2.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.